Compare Medpace Holdings Inc (MEDP) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Medpace Holdings Inc trades at $617.62 (market cap $16.82B), while Tencent Music Entertainment Group - ADR trades at $8.35 (market cap $12.83B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays a 3.02% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Tencent Music Entertainment Group - ADR for 67 Days on average.
| MEDP | TME | |
|---|---|---|
Market Cap | $16.82B | $12.83B |
Volume | 223,093 | 3,618,478 |
Sector | Health | Media |
52-Week High | $630.19 | $23.71 |
52-Week Low | $393.42 | $7.74 |
Typical Hold Time | 14 Days | 67 Days |
Enterprise Value | $16.44B | $10.77B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
TME trades at $8.38, up 4.88% today, but technical indicators are bearish overall. The company reported strong 2025 results with revenue of $32.9B and net income of $11.06B, though recent quarters show mixed earnings performance. Analyst sentiment is mixed with a consensus price target of $12.50, and the stock appears undervalued with a P/E of 9.33 and P/S of 2.46.
The outlook is balanced: attractive valuation and profitability support upside potential, but bearish technicals, competitive pressures, and recent net cash outflows pose risks. Investors should weigh strong fundamentals against near-term headwinds and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
